Oruka Therapeutics (ORKA) Research & Development (2010 - 2024)
Oruka Therapeutics (ORKA) posted quarterly Research & Development of $130000.0 for Q2 2024, down 48.82% year-over-year from $254000.0 in Q3 2023, and down 21.21% quarter-over-quarter from $165000.0 in Q1 2024.
Powered by 
Analysis
Oruka Therapeutics (ORKA) Research & Development (2010 - 2024) Analysis & Trends
Oruka Therapeutics' Research & Development history runs 15 years deep, the most recent figure standing at $130000.0 for Q2 2024.
- In Q2 2024, Research & Development fell 48.82% year-over-year to $130000.0; the TTM figure through Jun 2024 stood at $664000.0 (down 61.6% YoY), while the FY2023 annual figure was $1.0 million, down 78.67% from the prior year.
- Research & Development for Q2 2024 stood at $130000.0, down from $165000.0 in the prior quarter.
- The five-year high for Research & Development was $3.9 million in Q4 2021, with the low at $47000.0 in Q4 2023.
- The 5-year median for Research & Development is $707000.0 (2022), against an average of $1.4 million.
- The sharpest annual moves came in 2021 and 2022: Research & Development jumped 861.56% in 2021, then tumbled 98.45% in 2022.
- Oruka Therapeutics' Research & Development stood at $3.2 million in 2020, then gained by 23.0% to $3.9 million in 2021, then sank by 98.45% to $61000.0 in 2022, then declined by 22.95% to $47000.0 in 2023, then jumped by 176.6% to $130000.0 in 2024.
- Business Quant data shows ORKA's Research & Development at $130000.0 in Q2 2024, $165000.0 in Q1 2024, and $47000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | -486.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 651.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 394.92 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 612.28 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 97.90 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Oruka Therapeutics | 5.90 Bn | 4.17 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 130,000.00 |
| Mar 31, 2024 | 165,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Sep 30, 2023 | 322,000.00 |
| Jun 30, 2023 | 254,000.00 |
| Mar 31, 2023 | 390,000.00 |
| Dec 31, 2022 | 61,000.00 |
| Sep 30, 2022 | 1.02 Mn |
| Jun 30, 2022 | 1.49 Mn |
| Mar 31, 2022 | 2.18 Mn |
| Dec 31, 2021 | 3.94 Mn |
| Sep 30, 2021 | 3.44 Mn |
| Jun 30, 2021 | 3.58 Mn |
| Mar 31, 2021 | 2.88 Mn |
| Dec 31, 2020 | 3.20 Mn |
| Sep 30, 2020 | 1.05 Mn |
| Jun 30, 2020 | 372,000.00 |
| Mar 31, 2020 | 365,000.00 |
| Dec 31, 2019 | 384,000.00 |
| Sep 30, 2019 | 347,000.00 |